Goldman Sachs’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Goldman Sachs’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,348	Closed	-$370K	–	5794
2018 Q3	$370K	Buy	+28,348	New	+$366K	﹤0.01%	4587

Other funds holding ARDS

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's ARDS Position: Q4 2018 in Review

Goldman Sachs sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q4 2018, closing a stake of 28,348 shares — an estimated $370K sold.

Goldman Sachs first reported a position in ARDS in Q3 2018 and held it in 1 quarter. The position peaked at $370K in Q3 2018. 4 funds tracked by Wall St. Rank hold ARDS as of Q4 2018.

Goldman Sachs reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Goldman Sachs sold 28,348 Aridis Pharmaceuticals Inc. Common Stock shares in Q4 2018, an estimated $370K.
Goldman Sachs first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2018 and held it in 1 quarter.
Goldman Sachs's Aridis Pharmaceuticals Inc. Common Stock position peaked at $370K in Q3 2018.
4 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.